By Colin Kellaher
Insmed has won Food and Drug Administration priority review for its application seeking approval of its brensocatib drug candidate for patients with the chronic inflammatory condition non-cystic fibrosis bronchiectasis.
The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.
Insmed on Thursday said the FDA set a target action date of Aug. 12, adding that the agency hasn't indicated whether it will convene an advisory committee to discuss the application.
The Bridgewater, N.J., biopharmaceutical company said brensocatib has the potential to become the first and only approved treatment for non-cystic fibrosis bronchiectasis, which causes the lungs' airways to permanently widen and make the lungs more susceptible to infection.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 06, 2025 08:30 ET (13:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。